Chronic kidney disease bone and mineral disorder (CKD-MBD) in apolipoprotein E-deficient mice with chronic renal

Igor G Nikolov1, Nobuhiko Joki, Thao Nguyen-Khoa

  • 1Inserm ERI-12, University of Picardie, Amiens, France. nikolov_igor@yahoo.com

Bone
|April 22, 2010
PubMed

Insights

Apolipoprotein E deficiency increases bone mass in mice, with chronic renal failure (CRF) further elevating bone mass but decreasing bone density. These findings suggest a link between bone disease and vascular complications in chronic kidney disease (CKD).

Area of Science:

  • Nephrology
  • Bone Metabolism
  • Cardiovascular Disease

Background:

  • Chronic kidney disease (CKD) is linked to mineral and bone disorders (MBD), including renal osteodystrophy and vascular calcifications.
  • These MBDs may contribute to the high cardiovascular disease (CVD) risk in uremic patients.
  • Apolipoprotein E (ApoE) plays a role in both bone and lipid metabolism, making ApoE-deficient mice a relevant model for studying CKD-related bone and vascular issues.

Purpose of the Study:

  • To characterize bone lesions in CKD-apolipoprotein E-deficient (apoE(-/-)) mice.
  • To analyze the relationship between bone lesions and vascular calcifications in this model.
  • To compare the effects of chronic renal failure (CRF) on bone in apoE(-/-) mice versus wild-type (WT) mice.

Main Methods:

  • Female apoE(-/-) and WT mice underwent CRF creation or sham surgery.
  • Eight weeks post-surgery, serum, aorta, and femur samples were collected.
  • Femurs were analyzed using 3D microtomography (microCT) and bone histomorphometry (BHM); aortas were analyzed for atherosclerotic and calcified lesions.

Main Results:

  • ApoE deficiency increased cortical and trabecular bone mass in mice.
  • CRF further increased trabecular bone volume and osteoid surface in both genotypes.
  • Positive correlations were observed between atherosclerotic lesions and bone volume, and between plaque calcification and osteoclast parameters in apoE(-/-) mice.

Conclusions:

  • ApoE deficiency increases bone mass and volumetric mineral density in female mice.
  • CRF exacerbates bone mass increase but decreases bone mineral density, with signs of osteitis fibrosa.
  • Findings support a link between bone and vascular disease in CKD, warranting further investigation.
Abstract

Related Concept Videos

Chronic Kidney Disease II: Clinical Manifestations01:24

Chronic Kidney Disease II: Clinical Manifestations

Chronic Kidney Disease (CKD) progressively impairs multiple body systems due to the accumulation of uremic toxins, which disrupt cellular functions across various organs.Neurologic symptomsNeurologic symptoms often arise early in CKD, as uremic toxin buildup drives changes in cognitive and motor functions. Patients frequently experience fatigue, headache, confusion, difficulty concentrating, and, in severe cases, seizures. Peripheral neuropathy commonly manifests as burning sensations in the...
Chronic Kidney Disease I: Introduction01:25

Chronic Kidney Disease I: Introduction

Chronic Kidney Disease (CKD) arises when the kidneys progressively lose their ability to function, ultimately leading to end-stage renal disease. At this advanced stage, the kidneys can no longer filter waste or maintain essential body functions, requiring renal replacement therapy (RRT) through dialysis or a kidney transplant for survival.Early-stage chronic kidney disease and detection challengesIn CKD's early stages, symptoms often remain absent because healthy nephrons compensate for...
Chronic Kidney Disease III: Interprofessional Care01:28

Chronic Kidney Disease III: Interprofessional Care

Chronic kidney disease (CKD) requires collaborative and comprehensive management. CKD progresses through stages and can lead to end-stage kidney disease (ESKD) if untreated. Interprofessional collaboration and patient education are crucial, enabling patients to manage their health and improve their quality of life.Diagnostic approach for chronic kidney diseaseThe diagnosis of CKD primarily focuses on the glomerular filtration rate (GFR), which assesses kidney function by measuring how well...
Drug Dosing in Renal Diseases: Estimation of Glomerular Filtration Rate Based on Serum Creatinine Concentration01:28

Drug Dosing in Renal Diseases: Estimation of Glomerular Filtration Rate Based on Serum Creatinine Concentration

Glomerular filtration rate (GFR) can be estimated from serum creatinine using the modification of diet in renal disease (MDRD) formula or the chronic kidney disease–epidemiology collaboration (CKD–EPI) equation. Both methods are widely used in clinical practice to assess kidney function and guide treatment decisions.The MDRD equation does not require weight or height measurements and is normalized to the body surface area of 1.73 m², considered the average adult surface area. This equation is...
Diabetic Nephropathy01:28

Diabetic Nephropathy

Definition Diabetic nephropathy is a chronic kidney complication that results from prolonged hyperglycemia.Prevalence It is the most common cause of chronic kidney disease (CKD) and end-stage renal disease (ESRD) worldwide, affecting up to half of individuals with diabetes.Pathophysiology • Sustained hyperglycemia triggers multiple hemodynamic and metabolic changes in the kidney. • Early in the disease, increased renal blood flow and glomerular hyperfiltration occur due to afferent arteriolar...